Six Companies Went Public in the First Half, Down from Ten Last Year

Qualitative Indicators Improve, Including Offering Price and Institutional Lock-up Commitments

In the first half of this year, the IPO market for pharmaceutical, biotech, and medical device sectors achieved qualitative growth despite an overall decrease in the number of companies going public. While the number of newly listed companies declined, all companies that did debut on the stock market set their final offering prices at the upper end of their price ranges and saw high subscription competition, indicating a recovery in investor sentiment.


According to the industry on July 1, among the 17 companies newly listed on the stock market in the first half of the year, six were related to pharmaceuticals, biotech, and medical devices: Kanaph Therapeutics, IMBiologics, Inventera, Meju, and License Medical. This represents a quantitative decrease compared to the same period last year, when more than 10 companies from these sectors went public. This is interpreted as a result of the overall contraction of the IPO market and the rising bar for entry into the stock market for pharmaceutical and biotech companies.

Pharma and Biotech IPOs: Investor Sentiment Recovery or Selective Screening? View original image

However, a closer look at the listed companies reveals that qualitative indicators improved significantly compared to last year. All six companies listed in the first half of this year performed well in demand forecasts for institutional investors, setting their final offering prices at the top of their indicative price ranges. This contrasts with the first half of last year, when many companies had to set their offering prices below the lower end of their intended price bands or withdrew their IPOs altogether due to weak demand forecasts.


There was also a marked improvement in the mandatory holding commitment ratios among institutional investors. The mandatory holding commitment ratio—when investors pledge not to sell shares immediately after listing—serves as an indicator of the market’s confidence in the company's mid-to-long-term growth prospects. Last year, most newly listed companies had mandatory holding commitment ratios around 10%, raising concerns about early post-listing sell-offs. In contrast, this year, Kanaph Therapeutics recorded a ratio of 76.1% and IMBiologics 76.01%. Most companies in these sectors that went public in the first half of the year posted commitment ratios above 70%, reflecting a changed market sentiment.


The enthusiasm continued in the public subscription phase for retail investors. Meju achieved a high competition ratio of 2,428.3 to 1 in its general subscription, marking a successful debut, while License Medical also posted a competition ratio of 2,097.7 to 1. Most pharmaceutical and biotech companies that went public in the first half surpassed a competition ratio of 1,000 to 1 for retail subscriptions. This is a stark contrast to the first half of last year, when some companies faced lackluster interest from retail investors, resulting in low competition ratios.



Some analysts say this trend indicates that investors in the pharmaceutical and biotech IPO market are becoming more selective. An industry insider remarked, “Investors are moving away from indiscriminate investments and are instead focusing their funds on a select few companies with clear pipeline progress or technological capabilities. In an environment where the overall supply of newly listed shares is shrinking, differentiated outcomes—where only rigorously vetted and competitive companies are chosen by the market—are likely to persist for the time being.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing